Mysthera Therapeutics AG, a company developing first-in-class, oral therapeutics to treat complex autoimmune diseases, launched today with USD 3.5 million seed capital from founding investor Forty51 Ventures. The capital will be used to advance its portfolio of pre-clinical stage drug candidates.
MORE
